Glaxo, Valentis expand GeneSwitch technology license
Valentis Inc said it expanded its April 2001 license agreement with GlaxoSmithKline PLC to enable GlaxoSmithKline to use its GeneSwitch gene regulation technology for research purposes for up to 10 years.
Valentis will receive €1.1m under the expanded agreement.
CONNECT WITH US TODAY
Be the first to know the latest news and updates